Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review

被引：0
|
作者：
Nicolas Vandenbussche
Karolina Pisarek
Koen Paemeleire
机构：
[1] Ghent University Hospital,Department of Neurology
[2] Ghent University,Faculty of Medicine and Health Sciences
来源：
The Journal of Headache and Pain | / 24卷
关键词：
Methodology; Migraine; CGRP; Real-world evidence; Clinical trials;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review
    Vandenbussche, Nicolas
    Pisarek, Karolina
    Paemeleire, Koen
    JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01)
  • [2] Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data
    Sanchez-Rodriguez, Carmen
    Gago-Veiga, Ana Beatriz
    Garcia-Azorin, David
    Guerrero-Peral, Angel Luis
    Gonzalez-Martinez, Alicia
    CURRENT PAIN AND HEADACHE REPORTS, 2024, 28 (12) : 1265 - 1272
  • [3] The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study
    Torres-Ferrus, Marta
    Gallardo, Victor J.
    Alpuente, Alicia
    Caronna, Edoardo
    Gine-Cipres, Eulalia
    Pozo-Rosich, Patricia
    JOURNAL OF NEUROLOGY, 2021, 268 (10) : 3789 - 3798
  • [4] Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study
    Alpuente, Alicia
    Torre-Sune, Anna
    Caronna, Edoardo
    Gine-Cipres, Eulalia
    Torres-Ferrus, Marta
    Pozo-Rosich, Patricia
    CEPHALALGIA, 2023, 43 (08)
  • [5] The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study
    Marta Torres-Ferrús
    Victor J. Gallardo
    Alicia Alpuente
    Edoardo Caronna
    Eulalia Gine-Cipres
    Patricia Pozo-Rosich
    Journal of Neurology, 2021, 268 : 3789 - 3798
  • [6] Anti-CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years
    Pons-Fuster, E.
    Lozano-Caballero, O.
    Martin-Balbuena, S.
    Lucas-Rodenas, C.
    Mancebo-Gonzalez, A.
    De Gorostiza-Frias, I.
    Gonzalez-Ponce, C. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, : 1317 - 1326
  • [7] Brazilian descriptive study of 104 consecutive real-world migraine patients treated with monoclonal antibodies
    Krymchantowski, Abouch
    Silva-Neto, Raimundo Pereira
    Jevoux, Carla
    Krymchantowski, Ana Gabriela
    POSTGRADUATE MEDICINE, 2022, 134 (06) : 598 - 602
  • [8] CGRP Targeting Therapy for Chronic Migraine—Evidence from Clinical Trials and Real-world Studies
    Yen-Feng Wang
    Shuu-Jiun Wang
    Current Pain and Headache Reports, 2022, 26 : 543 - 554
  • [9] Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis
    Messina, Roberta
    Huessler, Eva-Maria
    Puledda, Francesca
    Haghdoost, Faraidoon
    Lebedeva, Elena R.
    Diener, Hans-Christoph
    CEPHALALGIA, 2023, 43 (03)
  • [10] CGRP Targeting Therapy for Chronic Migraine-Evidence from Clinical Trials and Real-world Studies
    Wang, Yen-Feng
    Wang, Shuu-Jiun
    CURRENT PAIN AND HEADACHE REPORTS, 2022, 26 (07) : 543 - 554
12345